A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
Status:
Completed
Trial end date:
2020-10-28
Target enrollment:
Participant gender:
Summary
The proposed study is an open-label, non-controlled, adaptive-design Phase II study to
evaluate the safety, pharmacodynamics, pharmacokinetics, efficacy, and conditions of use
(dosage, frequency of administration at maintenance) of ARGX-113 in patients with mild to
moderate Pemphigus (Vulgaris or Foliaceus), either newly diagnosed or relapsing.
The total study duration for each patient is less than 6 months. It consists of a Screening
period, an Induction, a maintenance treatment period followed by a treatment-free Follow-up
(FU) period.